Blueprint Medicines Signs an Exclusive Collaboration and License Agreement with Zai Lab to Develop and Commercialize BLU-945 and BLU-701 in Greater China
Shots: Blueprint will receive $25M up front, ~$590M in milestones along with royalties on net sales of BLU-945 & BLU-701 in Greater China & will retain all rights to BLU-945 & BLU-701 globally Zai Lab will get the rights to develop & exclusively commercialize BLU-945 & BLU-701 in Greater China & will lead the development […]